Trabectedin for the therapy of ovarian cancer

G. Evangelisti, F. Barra, G. D'Alessandro, M. Tantari, S. Stigliani, L. Della Corte, G. Bifulco, S. Ferrero

Research output: Contribution to journalReview articlepeer-review


Trabectedin is a marine-derivate antitumor drug with a relevant cytotoxic activity and good safety profile. It has been investigated for the treatment of solid diseases, including ovarian cancer (OC), breast cancer, and soft-tissue sarcoma. In 2009, results from the pivotal trial OVA-301 led the European Medicines Agency (EMA) to the approval of trabectedin in combination with PEGylated liposomal doxorubicin for the treatment of platinum-sensitive recurrent OC; further studies revealed an additional benefit also in the subgroup of patients with partially platinum-sensitive disease and in those with a BRCA-mutated status. Additionally, trabectedin was found to prolong the time interval to the subsequent chemotherapy line. Recently, the improved understanding of the antitumor action exerted by trabectedin paved the way to new investigational trials exploring its combination with targeted therapies.

Original languageEnglish
Pages (from-to)669-688
Number of pages20
JournalDrugs of Today
Issue number10
Publication statusPublished - Oct 2020


  • BRCA-mutated ovarian cancer
  • DNA-damaging drugs
  • Homologous recombination
  • IL-6 production inhibitors
  • Ovarian cancer therapy
  • Trabectedin
  • Tumor microenviroment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Trabectedin for the therapy of ovarian cancer'. Together they form a unique fingerprint.

Cite this